AgileBiotics

AGILeBiotics is developing novel next-generation aminoglycoside antibiotics for the treatment of multi-drug resistant (MDR) Gram-negative infections associated to high death rates, i.e. hospital- acquired- /ventilator-associated pneumonia (HAP/VAP), bloodstream infections (BSI) and neonatal sepsis. Our main focus is to find new antibiotic candidates active against carbepenem-resistant Enterobacteriaceae (CRE). In addition, AGILeBiotics is motivated to find novel treatment options for MDR tuberculosis and cystic fibrosis. In August 2019, Toframicin (ABX-605) has been selected for pre-clinical development, i.e. CMC and GLP-toxicity studies.